Companies: 10,795·Total market cap: $144.5T
InVivo Therapeutics Holdings Corporation

InVivo Therapeutics Holdings Corporation

NVIVNASDAQHealthcare
$0.32
$-0.17(-34.28%)
Market Cap$995918
P/E Ratio—
52W High$2.4
52W Low$0.22
Overview

InVivo Therapeutics Holdings Corporation (NVIV) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001292519 · NVIV · NASDAQ · as of Jun 9, 2026

Filing snapshot

883
Total Filings
25-NSE
Latest Form
2024-03-21
Most Recent
2010
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001292519 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-03-01
Fiscal Year End
Mar 1, 2023
Accession No.
0001558370-23-002588
Primary Document
nviv-20221231x10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001292519 · Accession 0001558370-23-002588

Latest Key Filings

10-QQuarterly Report
10-Q
2023-11-08
View 10-Q on SEC
8-KCurrent Report
FORM 8-K
2024-02-06Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
25-NSE25-NSE
25-NSE
2024-03-21
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-02-13
View
SC 13G/ABeneficial Ownership Report (Amended)
BRICE FOOSE
2024-02-06
View
8-KCurrent Report
FORM 8-K
2024-02-06
View
8-KCurrent Report
FORM 8-K
2024-02-01
View
8-KCurrent Report
FORM 8-K
2024-01-03
View
ARSARS
ARS
2023-12-05
View
DEF 14AProxy Statement
DEF 14A
2023-12-05
View
8-KCurrent Report
FORM 8-K
2023-12-01
View
8-KCurrent Report
FORM 8-K
2023-11-30
View
8-KCurrent Report
FORM 8-K
2023-11-22
View
10-QQuarterly Report
10-Q
2023-11-08
View
8-KCurrent Report
FORM 8-K
2023-09-01
View
10-QQuarterly Report
10-Q
2023-08-09
View
Showing 1–15 of 603 filingsForm 4 / 144 hidden· 883 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001292519  |  Exchange: NASDAQ · Healthcare

InVivo Therapeutics Holdings Corporation (NASDAQ: NVIV) has submitted 883 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2010. As a Healthcare sector company with CIK 0001292519, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is InVivo Therapeutics Holdings Corporation's most comprehensive regulatory disclosure. The most recent InVivo Therapeutics Holdings Corporation 10-K was filed on 2023-03-01 for fiscal year ending 2023. Historical NVIV 10-K annual reports are available from 2004 through 2023.

Investors researching InVivo Therapeutics Holdings Corporation SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
CWBR SEC Filings →TMBR SEC Filings →CYTO SEC Filings →IMPL SEC Filings →LSDI SEC Filings →AXDX SEC Filings →BLCM SEC Filings →INFIQ SEC Filings →
→ NVIV Financials→ NVIV Earnings→ NVIV Insider Trades

Frequently Asked Questions

NVIV SEC Filings · 8 questions

InVivo Therapeutics Holdings Corporation (NVIV) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 883 filings and access original documents at no cost. InVivo Therapeutics Holdings Corporation's CIK is 0001292519.

NVIV SEC filingsInVivo Therapeutics Holdings Corporation SEC documentsfind NVIV 10-K